MediciNova Reaches 100 Patients Enrolled in SEANOBI ALS Study for MN-166

Reuters01-30 07:00

MediciNova Reaches 100 Patients Enrolled in SEANOBI ALS Study for MN-166

MediciNova Inc. announced that 100 patients have been enrolled in the SEANOBI study, an Expanded-Access Program (EAP) evaluating MN-166 (ibudilast) in individuals with amyotrophic lateral sclerosis (ALS). The SEANOBI study, funded by a $22 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS initiative, has activated 12 sites in the United States and aims to enroll a total of 200 patients. The study is designed to provide access to MN-166 for ALS patients not eligible for ongoing randomized clinical trials and to collect clinical and biomarker data from a real-world population. In addition, MN-166 is being studied in the COMBAT-ALS Phase 2b/3 randomized, placebo-controlled trial with 234 patients enrolled in the U.S. and Canada. Top-line results from the COMBAT-ALS trial are expected by the end of 2026. No study results have been presented yet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645407-en) on January 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607057303?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 07:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607057303","market":"fut","top_or_hot":-1,"title":"MediciNova Reaches 100 Patients Enrolled in SEANOBI ALS Study for MN-166","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MediciNova Reaches 100 Patients Enrolled in SEANOBI ALS Study for MN-166\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MediciNova Inc. announced that 100 patients have been enrolled in the SEANOBI study, an Expanded-Access Program (EAP) evaluating MN-166 (ibudilast) in individuals with amyotrophic lateral sclerosis (ALS). The SEANOBI study, funded by a $22 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS initiative, has activated 12 sites in the United States and aims to enroll a total of 200 patients. The study is designed to provide access to MN-166 for ALS patients not eligible for ongoing randomized clinical trials and to collect clinical and biomarker data from a real-world population. In addition, MN-166 is being studied in the COMBAT-ALS Phase 2b/3 randomized, placebo-controlled trial with 234 patients enrolled in the U.S. and Canada. Top-line results from the COMBAT-ALS trial are expected by the end of 2026. No study results have been presented yet.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645407-en) on January 29, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MediciNova Reaches 100 Patients Enrolled in SEANOBI ALS Study for MN-166</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMediciNova Reaches 100 Patients Enrolled in SEANOBI ALS Study for MN-166\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-30 07:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MediciNova Reaches 100 Patients Enrolled in SEANOBI ALS Study for MN-166\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MediciNova Inc. announced that 100 patients have been enrolled in the SEANOBI study, an Expanded-Access Program (EAP) evaluating MN-166 (ibudilast) in individuals with amyotrophic lateral sclerosis (ALS). The SEANOBI study, funded by a $22 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS initiative, has activated 12 sites in the United States and aims to enroll a total of 200 patients. The study is designed to provide access to MN-166 for ALS patients not eligible for ongoing randomized clinical trials and to collect clinical and biomarker data from a real-world population. In addition, MN-166 is being studied in the COMBAT-ALS Phase 2b/3 randomized, placebo-controlled trial with 234 patients enrolled in the U.S. and Canada. Top-line results from the COMBAT-ALS trial are expected by the end of 2026. No study results have been presented yet.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645407-en) on January 29, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL3vKd8L:1","article_id":"2607057303","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607057303","pubTimestamp":1769727612,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MediciNova Inc. announced that 100 patients have been enrolled in the SEANOBI study, an Expanded-Access Program  evaluating MN-166  in individuals with amyotrophic lateral sclerosis . The SEANOBI study, funded by a $22 million grant from the National Institute of Neurological Disorders and Stroke  under the ACT for ALS initiative, has activated 12 sites in the United States and aims to enroll a total of 200 patients. The study is designed to provide access to MN-166 for ALS patients not eligible for ongoing randomized clinical trials and to collect clinical and biomarker data from a real-world population. In addition, MN-166 is being studied in the COMBAT-ALS Phase 2b/3 randomized, placebo-controlled trial with 234 patients enrolled in the U.S. and Canada. Top-line results from the COMBAT-ALS trial are expected by the end of 2026. No study results have been presented yet.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","MNOV":"美第奇新星生物技术","BK4139":"生物科技","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC"},"translate_title":"Medicinova MN-166 SEANOBI ALS研究招募了100名患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNOV":0.9,"NDAQ":0.9},"content_text":"MediciNova Reaches 100 Patients Enrolled in SEANOBI ALS Study for MN-166\n    \n\n        MediciNova Inc. announced that 100 patients have been enrolled in the SEANOBI study, an Expanded-Access Program (EAP) evaluating MN-166 (ibudilast) in individuals with amyotrophic lateral sclerosis (ALS). The SEANOBI study, funded by a $22 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS initiative, has activated 12 sites in the United States and aims to enroll a total of 200 patients. The study is designed to provide access to MN-166 for ALS patients not eligible for ongoing randomized clinical trials and to collect clinical and biomarker data from a real-world population. In addition, MN-166 is being studied in the COMBAT-ALS Phase 2b/3 randomized, placebo-controlled trial with 234 patients enrolled in the U.S. and Canada. Top-line results from the COMBAT-ALS trial are expected by the end of 2026. No study results have been presented yet.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645407-en) on January 29, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607057303","isCrawlerRequest":true}